ACRV Stock Summary and Trading Ideas (Acrivon Therapeutics | NASDAQ:ACRV)

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Acrivon Therapeutics trades on the NASDAQ stock market under the symbol ACRV.

As of March 18, 2026, ACRV stock price declined to $1.63 with 269,998 million shares trading.

ACRV has a beta of 2.12, meaning it tends to be more sensitive to market movements. ACRV has a correlation of 0.09 to the broad based SPY ETF.

ACRV has a market cap of $51.43 million. This is considered a Micro Cap stock.

In the last 3 years, ACRV traded as high as $20.07 and as low as $1.05.

The top ETF exchange traded funds that ACRV belongs to (by Net Assets): VTI, VXF, IWC.

ACRV has underperformed the market in the last year with a price return of -70.4% while the SPY ETF gained +18.6%. ACRV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.4% and -2.4%, respectively, while the SPY returned -0.6% and -2.2%, respectively.

ACRV support price is $1.56 and resistance is $1.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRV shares will trade within this expected range on the day.